A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Palbociclib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 18 Apr 2017 Results of pooled analysis (n=185) for development of semimechanistic population PK/PD model for understanding neutropenia associated with palbociclib using patient data from NCT00141297, NCT00420056, NCT00721409 trials, published in the Journal of Clinical Pharmacology
- 27 Oct 2015 Trial focus changed from PK+AR to PK+AR+TU. Endpoints has been added as per ClinicalTrials.gov record.
- 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.